drugset / Trial / NCT01397500
Hormone Treatment in Growth Hormone and Testosterone Deficient Patients
Phase 2
Terminated
54 enrolled
Max-Planck-Institute of Psychiatry
Schoen Clinic Bad Aibling · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Growth hormone and gonadotropin deficiency after brain injury (traumatic brain injury, ischemic stroke, subarachnoidal hemorrhage): the effects of hormone replacement on cognition, quality of life and body composition Randomized, controlled, 3 arm (group 2: double-blind; groups 1 and 3: open), multi-center, pilot study (Phase II)
Timeline
- Start
- 2011-11
- Primary completion
- 2015-02
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Somatropin | Protein / enzyme biologic | 0.2 mg | Subcutaneous |
| Comparator | Somatropin | Protein / enzyme biologic | 0.3 mg | Subcutaneous |
| Comparator | Somatropin | Protein / enzyme biologic | 0.4 mg | Subcutaneous |
| Comparator | Somatropin | Protein / enzyme biologic | 0.5 mg | Subcutaneous |
| Comparator | Testosterone undecannoate | Unknown | 1000 mg | Intramuscular |